An observational multi‐clinic implementation science study to evaluate barriers and enablers of real‐world use of confirmatory blood‐based biomarkers for the diagnosis of early Alzheimer’s disease

Documenti analoghi

• Observational Study Evaluating Blood‐Based Biomarker Use for Confirmatory Alzheimer's Disease Diagnosis in Real‐World Clinical Practice Within the United States
  di: Marwan N. Sabbagh, et al.
  Pubblicazione: (2025)
• Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's disease
  di: Michelle M. Mielke, et al.
  Pubblicazione: (2024)
• Real‐world analysis of the clinical care pathway of patients living with Alzheimer’s disease in the United States according to stage of cognitive impairment at diagnosis
  di: Elnara Fazio‐Eynullayeva, et al.
  Pubblicazione: (2024)
• Capacity for Alzheimer’s Disease confirmatory testing in the US ‐ current situation and simulations for future increase
  di: Sophie Roth, et al.
  Pubblicazione: (2024)
• Projected differences in wait times for diagnosis of Alzheimer’s disease for individuals dually eligible for Medicare and Medicaid in the U.S due to higher disease burden and obstacles to access
  di: Soeren Mattke, et al.
  Pubblicazione: (2024)